drugset
drugset / Trial / NCT07620366

To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis (F2-F3)

NCT07620366 ↗

Phase 2 Not yet recruiting 132 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-design clinical trial to evaluate efficacy and safety of QL2401 in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosis (F2-F3).

Timeline

Start
2026-06
Primary completion
2027-06
Completion
2028-03

Drugs

EvaluationDrugModalityDoseRoute
Subject QL2401 Protein / enzyme biologic 25 mg Subcutaneous
Subject QL2401 Protein / enzyme biologic 50 mg Subcutaneous
Subject QL2401 Protein / enzyme biologic 100 mg Subcutaneous

Indications

metabolic dysfunction-associated steatohepatitis